Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | GRM5 | P41594 | 5/20 | 0.34 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | HTR1F | P30939 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17770309 | 1.00 | CNR2 (0.35) | CNR2GRM5DEGS1AXLHTR1F | |
| SCHEMBL19714110 | 1.00 | CNR2 (0.35) | CNR2GRM5DEGS1AXLHTR1F | |
| SCHEMBL17770303 | 1.00 | CNR2 (0.35) | CNR2GRM5DEGS1AXLHTR1F | |
| SCHEMBL17769922 | 0.92 | KMT2A (0.37) | CNR2AXL | |
| SCHEMBL17769927 | 0.92 | KMT2A (0.37) | CNR2AXL | |
| SCHEMBL19714090 | 0.90 | GRM5 (0.35) | CNR2GRM5DEGS1HTR1FNTRK1 | |
| SCHEMBL17770445 | 0.90 | GRM5 (0.35) | CNR2GRM5DEGS1HTR1FNTRK1 | |
| SCHEMBL19714089 | 0.90 | GRM5 (0.35) | CNR2GRM5DEGS1HTR1FNTRK1 | |
| SCHEMBL17770440 | 0.90 | GRM5 (0.35) | CNR2GRM5DEGS1HTR1FNTRK1 | |
| SCHEMBL17769874 | 0.90 | CNR2 (0.37) | CNR2GRM5DEGS1HTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | disclosed |
| US-10072011-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2018-09-11 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072011-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | CNR2 3062/4885GRM5 3991/4885DEGS1 4276/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CNR2 3062/4885GRM5 3991/4885DEGS1 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.